Understand the source comparison
Peptides vs Standard Phantom Pain Treatments: Mechanisms Compared
Opioid Analgesics CNS pain receptor blockade 30–90 minutes None. Symptom suppression only Effective for acute pain; risk of tolerance and dependence with chronic use Gabapentin/Pregabalin Voltage-gated calcium channel inhibition 1–2 weeks None. Reduces nerve e
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Opioid Analgesics
- CNS pain receptor blockade
- 30–90 minutes
- None. Symptom suppression only
- Effective for acute pain; risk of tolerance and dependence with chronic use
- Gabapentin/Pregabalin
- Voltage-gated calcium channel inhibition
- 1–2 weeks
- None. Reduces nerve excitability without promoting repair
- First-line for neuropathic pain; 30–50% response rate in clinical trials
- Mirror Therapy
- Visual feedback cortical remapping
- 4–8 weeks
- Supports adaptive neuroplasticity through non-pharmacological means
- Evidence-based; no side effects; requires patient compliance and training
- BPC-157 Peptide
- VEGF-mediated peripheral nerve regeneration
- 2–4 weeks
- Promotes organized axonal regrowth and reduces neuroma formation
- Preclinical evidence strong; human trials pending; addresses root cause
- Thymalin Peptide
- Immune modulation, cytokine reduction
- 1–3 weeks
- Prevents chronic inflammatory sensitization at injury site
- Most effective in acute-to-subacute phase; limited chronic pain evidence
- Cerebrolysin
- Neurotrophic factor delivery, synaptic plasticity
- 2–6 weeks
- Supports adaptive cortical reorganization and neuronal survival
- Established in stroke recovery; phantom pain application exploratory